Introduction: Diabetes being one of the most common comorbidities of COVID-19, is prioritized for SARS-CoV-2 vaccination. To evaluate the T-cell mediated immune responses in T2DM, this study assessed and compared IFN-\(\gamma\) and IL-2 secreting PBMCs against the SARS-CoV-2 BNT162b2 mRNA vaccine. Methods: 19 known cases of type 2 diabetes and 16 healthy controls were included through purposive sampling and were regularly sampled before 1^st dose, after 1^st and 2^nd dose of vaccination. Ex-vivo ELISpot assays for IFN-\(\gamma\) and IL-2 were done using isolated PBMCs along with HbA1c status and SARS-CoV-2 spike-specific IgG antibody. A p-value < 0.05 was considered significant. Results: All participants were seroconverted after 1^st dose and showed a robust rise of IFN-\(\gamma\) and IL-2 secreting PBMCs counts in T2DM participants irrespective of hypertension, gender and age after 2 doses of vaccination. However, IFN-\(\gamma\) secreting PBMCs counts were significantly lower in type 2 diabetic group than healthy control group after 1^st dose. Conclusion: Although type 2 diabetic participants had a lower response initially, BNT162b2 mRNA vaccine overall induces a robust T-cell mediated immune response